Skip to main content

Advertisement

Table 3 Change1 in seropositive OD ratios between baseline (BL) and follow-up (FU)2 for BL seropositive cases

From: Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study

Change1 in OD Ratio HPV-16 E6 N = 22 HPV-16 E7
n = 20
  n (%) n (%)
BL to FU1   
   No decrease 8 (36.6) 10 (50.0)
   Decrease 14 (63.4) 10 (50.0)
p-value 3 0.10 0.50
BL to FU2   
   No decrease 3 (25.0) 4 (36.4)
   Decrease 9 (75.0) 7 (63.6)
p-value 3 0.04 0.19
BL to last FU   
   No decrease 6 (27.3) 7 (35.0)
   Decrease 16 (72.7) 13 (65.0)
p-value 3 0.02 0.09
  1. 1Based on ≥ 2-fold titration change using the last titration at each follow-up. 2FU1 = follow-up 1, FU2 = follow-up 2, FU = last follow-up, 3One-sided p-values for the binomial test that the proportion of patients who decreased was > 0.50.